Editas Medicine, Inc. (EDIT) reported a Q4 2025 loss of $0.06 per share, narrower by 72.1% compared to the consensus estimate of a $0.21 loss. The biotechnology company’s GAAP loss per share came in significantly better than Wall Street projections.
Revenue for the quarter totaled $24.74 million. No revenue estimate was available for comparison. The company trades on the NASDAQ exchange.
Shares of Editas Medicine traded at $1.90 following the earnings release. The narrower-than-expected loss represents a significant improvement versus analyst projections, though the company remains unprofitable as it continues development-stage operations typical of biotechnology firms.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.
